First-Line T-DXd Boosts PFS in HER2-Mutant NSCLC Frederik Joelving September 15, 2026

https://www.medscape.com/viewarticle/first-line-t-dxd-boosts-pfs-her2-mutant-nsclc-2026a1000y2a?src= First-line trastuzumab deruxtecan (T-DXd; ENHERTU) improves progression-free survival compared with standard chemoimmunotherapy in patients with advanced or metastatic HER2-mutant non-small cell lung cancer (NSCLC), according to new phase 3 data.